Research Perspectives:
Autophagydependent danger signaling and adaptive immunity to poorly immunogenic tumors
PDF | Full Text | How to cite
Guido Kroemer1,2,3,4,5,6,7 and Lorenzo Galluzzi1,2,3,4,8,9
1 Equipe 11 Labellisée par la Ligue Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France
2 INSERM, U1138, Paris, France
3 Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
4 Université Pierre et Marie Curie/Paris VI, Paris, France
5 Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France
6 Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP, Paris, France
7 Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden
8 Gustave Roussy Comprehensive Cancer Institute, Villejuif, France
9 Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
Correspondence to:
Lorenzo Galluzzi, email:
Keywords: ATP; chloroquine; damage-associated molecular patterns; doxorubicin; immunogenic cell death; radiation therapy
Received: October 27, 2016 Accepted: November 14, 2016 Published: December 10, 2016
Abstract
Recent data suggest that autophagy does not influence spontaneous and therapy-elicited tumor infiltration by immune cells in murine models of melanoma and breast carcinoma. These findings, which have been obtained in the absence of a therapeutically relevant anticancer immune response, indicate that the intrinsically low immunogenicity of some tumors cannot be compensated for by increased danger signaling.